One group was able to achieve improved responses at distal MCC metastases by injecting a TLR-4 agonist intratumorally at the primary MCC site followed by standard-of-care surgery and irradiation (Bhatia et al., 2019). Here, TLR4 is linked to Merkel cell skin cancer.